Current Issue
Displaying 6 results:
Original article
Safety, pharmacokinetics and pharmacodynamics of selgantolimod, an oral Toll-like receptor 8 agonist: a Phase Ia study in healthy subjects
Maribel Reyes, Justin D Lutz, Audrey H Lau, Anuj Gaggar, Ethan P Grant, Adarsh Joshi, Richard L Mackman, John Ling, Susanna K Tan, Natarajan Ayithan, Stephane Daffis, Jacky Woo, Peiwen Wu, Tina Lam, Simon P Fletcher, Shyamasundaran Kottilil, Bhawna Poonia, Edward J Gane, Anita Mathias, Polina German
Antiviral Therapy 2020; 25:171-180
Original article
Activation of HIV-specific CD8+ T-cells from HIV+ donors by vesatolimod
Renee R Ram, Paul Duatschek, Nicolas Margot, Michael Abram, Romas Geleziunas, Joseph Hesselgesser, Christian Callebaut
Antiviral Therapy 2020; 25:163-169
Original article
Antiviral activity of PLK1-targeting siRNA delivered by lipid nanoparticles in HBV-infected hepatocytes
Adrien Foca, Ammen Dhillon, Thomas Lahlali, Julie Lucifora, Anna Salvetti, Michel Rivoire, Amy Lee, David Durantel
Antiviral Therapy 2020; 25:151-162
Original article
Factors influencing hair lamivudine concentration among people living with HIV in Guangxi, China
Quan Zhang, Xiaoming Li, Shan Qiao, Zhiyong Shen, Yuejiao Zhou
Antiviral Therapy 2020; 25:143-149
Original article
Survival after long-term ART exposure: findings from an Asian patient population retained in care beyond 5 years on ART
Rimke Bijker, Sasisopin Kiertiburanakul, Nagalingeswaran Kumarasamy, Sanjay Pujari, Ly P Sun, Oon T Ng, Man P Lee, Jun Y Choi, Kinh V Nguyen, Yu J Chan, Tuti P Merati, Do D Cuong, Jeremy Ross, Awachana Jiamsakul, IeDEA Asia-Pacific
Antiviral Therapy 2020; 25:131-142
Original article
HBV flare associated with immunosuppressive treatments: it is still dangerous in the third-generation antivirals era
Bilal Toka, Aydin Seref Koksal, Gülşen İskender, Erol Çakmak, Oğuz Üsküdar, Mesut Sezikli, Göktuğ Şirin, Abdullah Emre Yildirim, Sami Fidan, Şencan Acar, Ahmet Tarik Eminler, Mustafa Ihsan Uslan, Sadettin Hülagü
Antiviral Therapy 2020; 25:121-129